The Experts below are selected from a list of 879 Experts worldwide ranked by ideXlab platform
Herbert Lepor - One of the best experts on this subject based on the ideXlab platform.
-
changes in nocturia from medical treatment of benign prostatic hyperplasia secondary analysis of the department of veterans affairs cooperative study trial
The Journal of Urology, 2003Co-Authors: Theodore M Johnson, Karen M Jones, William O Williford, Michael Kutner, Muta M Issa, Herbert LeporAbstract:ABSTRACTPurpose: We evaluate the efficacy of medical therapy on nocturia in men with benign prostatic hyperplasia (BPH).Materials and Methods: We performed a secondary analysis of data from the VA Cooperative Study Program Trial in which 1,229 men with BPH 45 to 80 years old were randomly assigned to receive Terazosin, finasteride, combination or placebo.Results: The 1,078 men who completed 12 months of the trial are included in this study. Of those men 1,040 (96.5%) had at least 1 episode of nocturia at baseline and 38 (3.5%) had less than 1 episode (baseline nocturia is an average of 2 measures). Of those 1,040 men 788 (75.8%) had 2 or more nocturia episodes. Overall, nocturia decreased from a baseline mean of 2.5 to 1.8, 2.1, 2.0 and 2.1 episodes in the Terazosin, finasteride, combination and placebo groups, respectively. Of men with 2 or more episodes of nocturia 50% reduction in nocturia was seen in 39%, 25%, 32% and 22% in the Terazosin, finasteride, combination and placebo groups, respectively. Cha...
-
effect of Terazosin on prostatism in men with normal and abnormal peak urinary flow rates
Urology, 1997Co-Authors: Herbert Lepor, Alan Nieder, Jean Feser, Caroline Oconnell, Christopher DixonAbstract:Objectives To determine if men with normal peak urinary flow rates (PFR) and prostatism respond to Terazosin.
-
the efficacy of Terazosin finasteride or both in benign prostatic hyperplasia veterans affairs cooperative studies benign prostatic hyperplasia study group
The New England Journal of Medicine, 1996Co-Authors: Herbert Lepor, William O Williford, Michael J Barry, Michael K Brawer, Christopher M Dixon, Glenn Gormley, Clair Haakenson, Madeline Machi, Perinchery Narayan, Robert J PadleyAbstract:Background Men with benign prostatic hyperplasia can be treated with α1-adrenergic–antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5α-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. Methods We compared the safety and efficacy of placebo, Terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year. Results The mean changes from base line in the symptom scores in the placebo, finasteride, Terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons of both Terazosin and combination therapy with finasteride and with placebo). The mean changes at one year in the peak urinary-flow rates were increases of 1.4, 1...
-
the efficacy of Terazosin finasteride or both in benign prostatic hyperplasia
The New England Journal of Medicine, 1996Co-Authors: Herbert Lepor, William O Williford, Michael J Barry, Michael K Brawer, Christopher M Dixon, Glenn Gormley, Clair Haakenson, Madeline Machi, Perinchery Narayan, Robert J PadleyAbstract:Background Men with benign prostatic hyperplasia can be treated with α1-adrenergic–antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5α-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared. Methods We compared the safety and efficacy of placebo, Terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year. Results The mean changes from base line in the symptom scores in the placebo, finasteride, Terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons of both Terazosin and combination therapy with finasteride and with placebo). The mean changes at one year in the peak urinary-flow rates were increases of 1.4, 1...
-
randomized double blind study comparing the efficacy of Terazosin versus placebo in women with prostatism like symptoms
The Journal of Urology, 1995Co-Authors: Herbert Lepor, Cindy TheuneAbstract:AbstractPurpose: We attempt to determine whether Terazosin is effective therapy for the treatment of prostatism-like symptoms in women.Materials and Methods: A total of 29 women 47 to 79 years old with prostatism-like symptoms entered a randomized double-blind study comparing Terazosin (14) versus placebo (15). The salient inclusion and exclusion criteria consisted of an American Urological Association (AUA) symptom score of 8 or more, post-void residual volume less than 300 ml. and absence of stress urinary incontinence.Results: The baseline and final visit AUA symptom scores were 12.7 and 10.7, respectively, in the placebo group, and 16.4 and 13.6, respectively, in the Terazosin group. The differences between the change in AUA symptom score in the placebo and Terazosin groups were not clinically or statistically significant.Conclusions: Our study demonstrates that Terazosin is not effective for the treatment of prostatism-like symptoms in aging women.
Michael Marberger - One of the best experts on this subject based on the ideXlab platform.
-
targeted transurethral microwave thermotherapy versus alpha blockade in benign prostatic hyperplasia outcomes at 18 months
Urology, 2001Co-Authors: Bob Djavan, Claus G Roehrborn, Ali Basharkhah, Christian Seitz, Mesut Remzi, Mitra Fakhari, Matthias Waldert, Bernhard Planz, Mike Harik, Michael MarbergerAbstract:Abstract Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received Terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of Terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the Terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater ( P Conclusions. Although the initial onset of Terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months.
-
prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha blocker treatment of patients with benign prostatic hyperplasia
The Journal of Urology, 1999Co-Authors: Bob Djavan, Claus G Roehrborn, Shahrokh F Shariat, Keywan Ghawidel, Michael MarbergerAbstract:AbstractPurpose: We compare directly the efficacy and safety of targeted high energy transurethral microwave thermotherapy with alpha-blocker treatment for benign prostatic hyperplasia (BPH).Materials and Methods: In this randomized prospective study 52 patients with symptomatic BPH received Terazosin and 51 underwent high energy transurethral microwave therapy with topical anesthesia. Patient evaluation included determination of International Prostate Symptom Score (I-PSS), peak flow rate and quality of life score before transurethral microwave therapy or Terazosin and periodically up to 6 months thereafter.Results: At 2-week followup the Terazosin group transiently exhibited significantly greater improvement than the transurethral microwave therapy group in mean values of all 3 primary efficacy parameters of I-PSS, peak flow rate and quality of life score. At 12 weeks and 6 months this pattern was reversed, and the transurethral microwave therapy group achieved significantly greater improvement than the...
Bob Djavan - One of the best experts on this subject based on the ideXlab platform.
-
targeted transurethral microwave thermotherapy versus alpha blockade in benign prostatic hyperplasia outcomes at 18 months
Urology, 2001Co-Authors: Bob Djavan, Claus G Roehrborn, Ali Basharkhah, Christian Seitz, Mesut Remzi, Mitra Fakhari, Matthias Waldert, Bernhard Planz, Mike Harik, Michael MarbergerAbstract:Abstract Objectives. To compare directly the efficacy, safety, and durability of targeted transurethral microwave thermotherapy with that of alpha-blocker treatment for lower urinary tract symptoms of benign prostatic hyperplasia. Methods. In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received Terazosin treatment and 51 underwent microwave treatment under topical anesthesia. The patient evaluation included the International Prostate Symptom Score, peak flow rate, and quality-of-life score before microwave treatment or initiation of Terazosin treatment and at periodic intervals thereafter up to 18 months. Results. The mean International Prostate Symptom Score, peak flow rate, and quality-of-life score all improved significantly in both groups by 6 months. However, the magnitude of improvement was significantly greater in the microwave group than in the Terazosin group. The significant between-group differences observed at 6 months in the mean International Prostate Symptom Score, peak flow rate, and quality-of-life score were fully maintained at 18 months, at which time the improvements in these three outcome measures were significantly greater ( P Conclusions. Although the initial onset of Terazosin action was more rapid, the longer term clinical outcomes of targeted microwave treatment were markedly superior. The more favorable results in patients who underwent microwave treatment were maintained for at least 18 months.
-
prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha blocker treatment of patients with benign prostatic hyperplasia
The Journal of Urology, 1999Co-Authors: Bob Djavan, Claus G Roehrborn, Shahrokh F Shariat, Keywan Ghawidel, Michael MarbergerAbstract:AbstractPurpose: We compare directly the efficacy and safety of targeted high energy transurethral microwave thermotherapy with alpha-blocker treatment for benign prostatic hyperplasia (BPH).Materials and Methods: In this randomized prospective study 52 patients with symptomatic BPH received Terazosin and 51 underwent high energy transurethral microwave therapy with topical anesthesia. Patient evaluation included determination of International Prostate Symptom Score (I-PSS), peak flow rate and quality of life score before transurethral microwave therapy or Terazosin and periodically up to 6 months thereafter.Results: At 2-week followup the Terazosin group transiently exhibited significantly greater improvement than the transurethral microwave therapy group in mean values of all 3 primary efficacy parameters of I-PSS, peak flow rate and quality of life score. At 12 weeks and 6 months this pattern was reversed, and the transurethral microwave therapy group achieved significantly greater improvement than the...
Joanna K Chon - One of the best experts on this subject based on the ideXlab platform.
-
alpha1 adrenoceptor antagonists Terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
The Journal of Urology, 1999Co-Authors: Joanna K Chon, Andrew Borkowski, Alan Wayne Partin, John Tod IsaacsAbstract:AbstractPurpose: Recent evidence indicated that an alpha1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH).[1] in this study, to determine whether this apoptotic response was mediated by alpha1 adrenoceptor-dependent mechanism or was specific to doxazosin, we examined the effect of another alpha1 blocker, Terazosin, in addition to doxazosin, on the dynamics of prostate cell growth.Materials and Methods: Cell proliferation and apoptosis were evaluated in BPH patients, an untreated (control) group (n = 31), and men treated with Terazosin (n = 42) and doxazosin (n = 61) for the relief of the obstructive symptoms. Terazosin (1 to 10 mg./day) and doxazosin (2 to 8 mg./day) treatment varied from 1 week to 3 years. Ki-67 immunostaining and the TUNEL assay were used to evaluate the proliferative and apoptotic indices, respectively, in both the epithelial and stromal components of prostate (biopsy and prostatectomy) specimens. The smooth muscle cell content of the ...
John N Krieger - One of the best experts on this subject based on the ideXlab platform.
-
DOI: 10.1097/01.ju.0000042927.45683.6c Terazosin THERAPY FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: A RANDOMIZED, PLACEBO CONTROLLED TRIAL
2013Co-Authors: Timothy Khor, Jin Rong Yang, Hin Wai, John N KriegerAbstract:Purpose: We evaluate Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome. Materials and Methods: The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous �-blockers. Subjects were randomized to receive Terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less (“delighted-to-mostly satisfied”) on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50 % reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects. Results: Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the Terazosin group compared to 14 of 43 (36%) in the placebo group (p � 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the Terazosin group compared to 16 of 43 (37%) in the placebo group (p � 0.03). The Terazosin group had greater reductions (p �0.05) in NIH-CPS
-
Terazosin therapy for chronic prostatitis chronic pelvic pain syndrome a randomized placebo controlled trial
The Journal of Urology, 2003Co-Authors: Phaik Yeong Cheah, Men Long Liong, Kah Hay Yuen, Timothy Khor, Jin Rong Yang, John N KriegerAbstract:ABSTRACTPurpose: We evaluate Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome.Materials and Methods: The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous α-blockers. Subjects were randomized to receive Terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less (“delighted-to-mostly satisfied”) on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects.Results: Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the Terazosin group compared to 14 of 43 (36%) in the plac...
